MorphoSys AG has increased its share capital with the issue of 1,337,552 new ordinary shares to a subsidiary of Royalty Pharma Plc as part of a long-term financial partnership that is enabling the German company to acquire Constellation Pharmaceuticals Inc of the US. The share deal will generate $100 million for MorphoSys and give Royalty Pharma Investments 3.9% of the German company’s registered share capital. MorphoSys completed the acquisition of Constellation on 15 July, giving it one of the first US companies to develop drugs in the field of epigenetics.
